We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 22, 2022

Radiation in Patients With ALK-Positive Lung Cancer and Newly Diagnosed Brain Metastasis Receiving First-Line ALK Inhibitor

International Journal of Radiation Oncology, Biology, Physics


Additional Info

Disclosure statements are available on the authors' profiles:

International Journal of Radiation Oncology, Biology, Physics
Real world use of radiation for newly diagnosed brain metastases in ALK-positive lung cancer receiving a first line ALK inhibitor
Int. J. Radiat. Oncol. Biol. Phys 2022 Jul 20;[EPub Ahead of Print], S Kumar, X Wang, H Pittell, GS Calip, SE Weiss, JE Meyer, TJ Royce

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading